Affiliations: [a]
Nemo Sud Clinical Centre for Neuromuscular Disorders, Messina, Italy
| [b]
Cardiomyology and Medical Genetics, Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
| [c] IRCCS Mondino Foundation, Pavia, Italy
| [d]
Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
Correspondence:
[*]
Correspondence to: Giuseppe Vita, Unit of Neurology and Neuromuscular Diseases, Messina University Policlinico Hospital, Via Consolare Valeria 1, 98125 Messina, Italy. Tel.: +39 090 2217309; E-mail: giuseppe.vita@unime.it.
Abstract: Background:Increasing evidence suggests that Duchenne muscular dystrophy (DMD) gene is involved in the occurrence of different types of cancer. Moreover, development of sarcomas was reported in mdx mice, the murine model of DMD, in older age. So far, nine isolated DMD patients were reported with concomitant cancer, four of whom with rhabdomyosarcoma (RMS), but no systematic investigation was performed about the true incidence of cancer in DMD. Methods:All members of the Italian Association of Myology were asked about the occurrence of cancer in their DMD patients in the last 30 years. Results:Four DMD patients with cancer were reported after checking 2455 medical records. One developed brain tumour at the age of 35 years. Two patients had alveolar RMS at 14 and 17 years of age. The fourth patient had a benign enchondroma when 11-year-old. Conclusion:Prevalence of cancer in general in the Italian DMD patients does not seem to be different from that in the general population with the same age range. Although the small numbers herein presented do not allow definitive conclusion, the frequent occurrence of RMS in DMD patients raises an alert for basic researchers and clinicians. The role of DMD gene in cancer merits further investigations.
